相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New and Emerging Therapies for Bone Metastases in Genitourinary Cancers
Philip J. Saylor et al.
EUROPEAN UROLOGY (2013)
Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
Matthew R. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Recent developments in treatments targeting castration-resistant prostate cancer bone metastases
Y. Loriot et al.
ANNALS OF ONCOLOGY (2012)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R. Smith et al.
LANCET (2012)
Management of bone metastases in refractory prostate cancer - role of denosumab
Channing J. Paller et al.
CLINICAL INTERVENTIONS IN AGING (2012)
A short account of metastatic bone disease
Liviu Feller et al.
CANCER CELL INTERNATIONAL (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Microarchitectural Deterioration of Cortical and Trabecular Bone: Differing Effects of Denosumab and Alendronate
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Zoledronic Acid Improves Clinical Outcomes When Administered Before Onset of Bone Pain in Patients With Prostate Cancer
Fred Saad et al.
UROLOGY (2010)
Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL
Paul J. Kostenuik et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Bisphosphonates: Mechanism of action and role in clinical practice
Mathew T. Drake et al.
MAYO CLINIC PROCEEDINGS (2008)
Anti-resorptive therapies for osteoporosis
Ian R. Reid
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease
Fred Saad et al.
SEMINARS IN ONCOLOGY (2007)
Biology of RANK, RANKL, and osteoprotegerin
Brendan F. Boyce et al.
ARTHRITIS RESEARCH & THERAPY (2007)
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases
Theresa A. Guise et al.
CLINICAL CANCER RESEARCH (2006)
Clinical features of metastatic bone disease and risk of skeletal morbidity
Robert E. Coleman
CLINICAL CANCER RESEARCH (2006)
A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions
RD Loberg et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank
RP Kapur et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The role of bisphosphonates in breast and prostate cancers
JE Brown et al.
ENDOCRINE-RELATED CANCER (2004)
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
AV D'Amico et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Genetic regulation of osteoclast development and function
SL Teitelbaum et al.
NATURE REVIEWS GENETICS (2003)
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts
H Takayanagi et al.
DEVELOPMENTAL CELL (2002)
Reaching a genetic and molecular understanding of skeletal development
G Karsenty et al.
DEVELOPMENTAL CELL (2002)
分享论文
